Bristol Myers Squibb Company $BMY Shares Sold by United Advisor Group LLC

United Advisor Group LLC lessened its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 33.4% in the third quarter, HoldingsChannel reports. The firm owned 18,796 shares of the biopharmaceutical company’s stock after selling 9,428 shares during the quarter. United Advisor Group LLC’s holdings in Bristol Myers Squibb were worth $1,173,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in BMY. Davis Asset Management L.P. acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth about $27,000. Addison Advisors LLC purchased a new stake in shares of Bristol Myers Squibb during the second quarter worth about $32,000. Groupe la Francaise raised its position in shares of Bristol Myers Squibb by 562.9% in the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 501 shares during the last quarter. Arlington Trust Co LLC acquired a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $35,000. Finally, Kilter Group LLC acquired a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $35,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of analyst reports. Royal Bank Of Canada restated a “sector perform” rating on shares of Bristol Myers Squibb in a research report on Monday, October 19th. The Goldman Sachs Group upgraded Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Friday, October 16th. Zacks Research lowered Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 22nd. Leerink Partners cut Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $73.00 to $59.00 in a report on Monday, October 5th. Finally, Wells Fargo & Company lowered their price objective on Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $65.46.

Bristol Myers Squibb Trading Down 1.5%

NYSE BMY opened at $62.20 on Friday. The company has a market cap of $127.15 billion, a P/E ratio of 13.79, a P/E/G ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a 12 month low of $45.26 and a 12 month high of $68.64. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. The company has a 50-day moving average of $62.34 and a 200-day moving average of $60.11.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The business had revenue of $13.07 billion for the quarter, compared to analysts’ expectations of $12.72 billion. During the same period last year, the company earned $1.63 earnings per share. The company’s quarterly revenue was up 6.9% on a year-over-year basis. As a group, equities analysts predict that Bristol Myers Squibb Company will post 6.45 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.88%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Insiders Place Their Bets

In other news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Julia A. Haller sold 3,800 shares of the stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the transaction, the director directly owned 30,279 shares in the company, valued at $1,916,963.49. This trade represents a 11.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.05% of the stock is owned by company insiders.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.